| Trial ID: | L0147 |
| Source ID: | NCT01355575
|
| Associated Drug: |
Rifaximin
|
| Title: |
Rifaximin in Fatty Liver Disease
|
| Acronym: |
RiFL
|
| Status: |
Terminated
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT01355575/results
|
| Conditions: |
Nonalcoholic Fatty Liver Disease|NAFLD|Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Rifaximin
|
| Outcome Measures: |
Serum Alanine Aminotransferase (ALT) Levels|Insulin Resistance|Hepatic Triglyceride Content
|
| Sponsor/Collaborators: |
Imperial College London|National Health Service, United Kingdom
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
15
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
May 2011
|
| Completion Date: |
September 2012
|
| Results First Posted: |
September 4, 2020
|
| Last Update Posted: |
October 28, 2020
|
| Locations: |
Liver Unit, St Mary's Hospital, Imperial College London, London, United Kingdom
|
| URL: |
https://ClinicalTrials.gov/show/NCT01355575
|
